[A19-73] Ramucirumab (hepatocellular carcinoma) - Benefit assessment according to §35a Social Code Book V
Last updated 02.12.2019
Project no.:
A19-73
Commission:
Commission awarded on 29.08.2019 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of ≥ 400 ng/mL and who have been previously treated with sorafenib
Negative effects in some side effects do not call into question the major advantage in overall survival; overall proof of considerable added benefit
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A20-13 | Ramucirumab (NSCLC, combination with erlotinib) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A20-03 | Ramucirumab (hepatocellular carcinoma) - Addendum to Commission A19-73 | Commission completed |
| G15-02 | Ramucirumab - Assessment according to §35a (para. 1., sentence 10) Social Code Book V (dossier assessment) | Commission completed |
| A16-23 | Ramucirumab - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-11 | Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-10 | Ramucirumab (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V | Commission completed |
| A16-50 | Ramucirumab (colorectal cancer) - Addendum to Commission A16-10 | Commission completed |
Federal Joint Committee (G-BA)
2020-02-20 A G-BA decision was published.